Close Menu

Ambry

MSK's PathoMAN achieved 94 percent and 81 percent concordance with results from three commercial labs for pathogenic and benign variants, respectively.

The article argues that PRS are bad at identifying those who will develop disease but others say this is the same for widely used risk factors.

CMS's move to restrict coverage could limit test access for early-stage cancer patients and negatively impact lab revenues.

Among the firms presenting, 10x noted that it doubled its revenue growth in 2018, and Myriad discussed the impact that new tests are having on its growth.

Genetic counselors, laboratories, and patients themselves have roles to play in reclassifying gene variants, including variants of uncertain significance.

The 72-SNP score is for men of European ancestry who don't have mutations in high penetrance risk genes or mutations in genes associated with aggressive disease.

KMPJM will provide diagnostic and prognostic testing services based on genes, proteins, and other molecules to aid physicians in assessing and treating patients.

The team also elucidated well-established and controversial non-BRCA predisposition genes associated with breast or ovarian cancer.

The effort will provide individuals with genetic testing to determine if they have the disorder, and when necessary,  with genetic testing counselling.

Ambry will offer ArcherDX's immune repertoire sequencing assays to biopharmaceutical customers.

Pages

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.